

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this supplemental notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this supplemental notice.



CARsgen Therapeutics Holdings Limited

科濟藥業控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2171)

SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING

References are made to the (i) the circular of CARsgen Therapeutics Holdings Limited (the “**Company**”) dated 18 April 2024 (the “**Circular**”); (ii) the notice of the annual general meeting of the Company dated 18 April 2024 (the “**Original Notice**”) to convene the annual general meeting of the Company (the “**Annual General Meeting**”) at 1F, Building 2, No. 466 Yindu Road, Xuhui District, Shanghai, the PRC on Tuesday, 21 May 2024 at 10:00 a.m.; and (iii) the supplemental circular of the Company date 30 April 2024.

Details of the proposed resolutions to be considered at the Annual General Meeting were stated in the Original Notice. Unless otherwise stated, terms defined herein shall have the same meanings as those defined in the Circular. Apart from the amendments stated below, all the information contained in the Original Notice remains to have full force and effect, and this supplemental notice shall be read together with the Original Notice:

SUPPLEMENTAL NOTICE IS HEREBY GIVEN THAT:

In addition to the resolutions set out in the Original Notice, the Annual General Meeting will be held to consider and, if thought fit, pass the following additional resolution:

Ordinary Resolution

12. To re-elect Dr. Wen ZHOU as an independent non-executive director of the Company.

By Order of the Board
CARsgen Therapeutics Holdings Limited
Dr. Zonghai LI
Chairman

Hong Kong, 30 April 2024

Notes:

1. A second form of proxy (the “**Revised Proxy Form**”) containing the ordinary resolution numbered 12 is enclosed with the supplemental circular of the Company dated 30 April 2024 (the “**Supplemental Circular**”). Please refer to the section headed “Supplemental Notice of Annual General Meeting and Revised Proxy Form” on pages 4 to 5 of the Supplemental Circular for arrangements on the completion and submission of the Revised Proxy Form.
2. Please refer to the Original Notice for details of the other resolutions to be considered at the Annual General Meeting, closure of the register of members of the Company and eligibility for attending the Annual General Meeting, proxy and other relevant matters.
3. References to time and dates in this notice are to Hong Kong time and dates.

As at the date of this supplemental notice, the board of directors of the Company comprises Dr. Zonghai LI, Dr. Huamao WANG and Dr. Hua JIANG as executive Directors; Mr. Bingsen GUO, Mr. Huaqing GUO and Mr. Ronggang XIE as non-executive Directors; Dr. Guangmei YAN, Ms. Xiangke ZHAO and Dr. Wen ZHOU as the independent non-executive Directors.

In the case of inconsistency, the English text of this notice shall prevail over the Chinese text.